The global sodium acetate trihydrate & sodium acetate anhydrous market is estimated to be valued at US$136.98 billion in 2024 and is expected to exhibit a CAGR of 9.5% over the forecast period of 2024 to 2031.

Key players operating in the Sodium Acetate Trihydrate & Anhydrous Market are AbbVie Inc., Ablynx NV by Sanofi SA, Arrowhead Pharmaceuticals, Inc., Baxter International Inc., AstraZeneca PLC, Boston Scientific Corporation, Becton, Depomed, Inc., Fraunhofer Gesellschaft Munchen, Janssen Global Services, LLC., Luye Pharma Group, Pfizer Inc., Quark Pharmaceuticals Inc., Rexahn Pharmaceuticals Inc., Savara Inc., Roche Holding AG, Suda Limited, Vectura Group PLC, Taiwan Liposome Company, Ltd., and 3M Company. 

Among all geographical regions, Asia Pacific is expected to witness the highest growth in the sodium acetate trihydrate & sodium acetate anhydrous market during the forecast period of 2024 to 2031. Demand is projected to increase at a CAGR of 11% in Asia-Pacific. This fast pace of growth can be attributed to factors like the rising pharmaceutical industry and improving healthcare infrastructure in the region. In particular, China and India are anticipated to majorly drive the market due to their large population sizes and increasing per capita health expenditures in these countries. Additionally, Asia Pacific presents significant opportunities for exports of sodium acetate from North America and Europe into emerging economies.

Get more insights on Sodium Acetate Market